Company and Stock Identity

How Anumana Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Ask which patients each algorithm was tested on. Anumana's cardiac amyloidosis figures, 78.9 percent sensitivity and 91.2 percent specificity, are company data on file from 25,525 patients at four United States health systems, and the pulmonary hypertension algorithm was built from Mayo Clinic records. Numbers from those groups are not a promise for a different patient mix.

Anumana says on its own site that it was founded in 2021 out of a joint effort between Mayo Clinic and nference. Checked on 2026-10-10 against the company site and its press release index, with no ownership change found.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Anumana ... Company source

Anumana gets FDA clearance for reading cardiac amyloidosis from a standard ECG

Anumana said on 8 April 2026 that the FDA cleared its ECG-AI algorithm for cardiac amyloidosis read from a standard 12-lead ECG, and the company calls it the first and only one cleared for that use on a standard 12-lead test. Anumana reports 78.9 percent sensitivity and 91.2 percent specificity in adults, from company data on file covering 25,525 patients at four United States health systems. The company also says the device had earlier received FDA Breakthrough Device Designation.

Why it matters: Hospitals already record ECGs by the million, so a cleared algorithm that reads an existing test costs less to add than a new scanner. The performance figures are the company's own data on file rather than an independent trial, and a sensitivity of 78.9 percent means roughly one in five people with the condition in that study group was not flagged. Clearance means the FDA accepted the submission for this use. It does not show how the algorithm will behave on a different patient mix.

... Anumana ... Company source

Anumana gets FDA clearance for spotting pulmonary hypertension on an ECG

Anumana said on 28 March 2026 that it received FDA 510(k) clearance for an ECG-AI algorithm that looks for pulmonary hypertension on a standard 12-lead ECG, and the company describes it as the first such algorithm cleared for that test. Anumana reports 73 percent sensitivity and 74.4 percent specificity in adults who came in short of breath, from a multi-centre study of 21,066 patients at five United States health systems. The company says the algorithm was developed using more than 250,000 de-identified patient records from Mayo Clinic.

Why it matters: Pulmonary hypertension is usually confirmed with tests that cost more and take longer than an ECG, so a cleared screening signal on a cheap test is worth a look for a cardiology service line. The reported specificity of 74.4 percent also means a large number of people without the condition would be flagged, and somebody has to work through those results. A buyer should price the follow-up workload, not only the software.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers page names data scientists, software engineers, clinical researchers and commercial strategists, and points people to a careers email rather than a job board.

Qualification signal: Work that sits between heart care and AI counts most here, because every product is an ECG algorithm that has to clear the FDA. Shipping a regulated device matters more than general AI experience.

Check current roles at Anumana. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
CMIO, quality and safety, nursing leadership, clinical informatics, data science, and service-line owners
Primary use case
Surface patient risk, deterioration signals, or clinical recommendations for review
Typical deployment
Usually embedded in the EHR or connected to streaming clinical data with alerts delivered inside existing workflows

Evidence questions

  • What population, prevalence, and care setting were used for validation?
  • Has the tool been tested prospectively against the current workflow?
  • What clinical and operational outcomes improved beyond model accuracy?

Regulatory and workflow questions

  • Does the intended use place the software under FDA device oversight?
  • What does the clinician see before acting on the score or alert?
  • Who owns performance review, adverse event review, and suspension decisions?

Data and contract questions

  • Which inputs are required and how are missing or delayed data handled?
  • How are model updates, feature changes, and drift disclosed?
  • Can local performance be measured by patient subgroup and clinical unit?

Evidence and Regulation

FDA Clearances on Record

Anumana appears on 4 cleared products in the federal 510(k) record, across 3 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources